Arecor and GSK Sign Vax License Deal

GSK and Arecor will work to develop new approaches that could offer significant improvements to the administration of several vaccines in development.

Cambridge biotech business Arecor and healthcare giant GlaxoSmithKline have signed a licensing pact to develop advanced formulations of vaccines combining Arecor’s formulation technologies with GSK’s proprietary vaccines.

GSK and Arecor will work to develop new approaches that could offer significant improvements to the administration of several vaccines in development. Arecor will receive payments on relevant development milestones and royalties on sales.

Tom Saylor, chief executive officer of Arecor, said, “Arecor is pleased to work closely with one of the global leaders in vaccine products and technology. The relationship with GSK offers Arecor the potential to apply its broad-ranging expertise in biomolecule stabilization to specific projects with GSK.”